ViAqua Therapeutics was established in September 2014 to address the growing need for effective, affordable health management of diseases in aquaculture. To date, ViAqua has received investments from The Trendlines Group, Nutreco, VisVires New Protein, S2G Ventures, Thai Union, and the Technion–Israel Institute of Technology, with support from the Israel Innovation Authority.
Q4 2021: Name Chris Beattie, Ph.D., as an active director
Q2 2021: Add S2G Ventures as financial investors and Thai Union as strategic investors
2021: Prove the stability of the product in industrial feed production process; developed an innovative, cost-effective, scalable production process and successfully reached pilot scale
2019: Prepare for high-volume manufacturing and improved product efficacy
Q3 2018: Sign joint development agreement with Skretting SA (Nutreco’s aquaculture division) for first product, including distribution and marketing by Skretting
Q3 2018: Receive investment from Nutreco and VisVires New Protein
Q1 2018: Proof-of-concept for oral delivery of first product
ViAqua’s co-founders have Ph.D.s in molecular biology and marine biology, respectively. The Company’s management bring a broad range of business development, technology development, management, and industrial biotech experience.
Shai Ufaz, Ph.D.
CEO & Co-Founder
Molecular biologist; experience in biotechnology, genetic engineering, protein expression; project manager, Protalix Biotherapeutics, TransAlgae; PhD, plant genetics
Shai Einbinder, Ph.D.
Marine biologist; experience in product development, management; VP Development & Projects, TransAlgae; CEO, Aurora-V; PhD, marine biology
Prof. Avi Schroeder
Extensive development in fields of RNA and protein delivery and nanotechnology; Asst. Prof. of Chemical Engineering, Technion-Israel Institute of Technology; postdoctoral fellow with Prof. Robert Langer, MIT
Chris Beattie, Ph.D.
Active Director of ViAqua Therapeutics
Chief Scientific Officer for AquaBounty
"Champion of Innovation"
AquaBounty, a land-based salmon producer innovating to enhance productivity and sustainability in aquaculture, has announced that Dr Chris Beattie will lead the research and development, compliance and regulatory functions of the company as Chief Scientific Officer in July 2022. Dr Beattie will retain his position as an active director of ViAqua Therapeutics, which he has held since 2021.More than 30 years' experience that combines a strong scientific understanding (PhD, fish physiology) with extensive commercial experience at AKVA Group, Merck, and Skretting North America. Based in Vancouver, Canada, Chris leads AKVA Group's North American and Australasian aquaculture technology business
Ami Schlesinger, Ph.D., MBA
Executive VP Business Development
Marine zoologist with extensive business experience; previously, researcher at TransAlgae; director of R&D at Nanocyte; and executive chairman of business at Ma'agan Michael. Led several firms in senior executive positions spanning diverse fields, including agriculture, aquaculture, desalination, cleantech, energy, trading, precision technology, and plastic